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AKTIn previous works, we found that PTH promotes the apoptosis of human Caco-2 intestinal cells, through the
mitochondrial pathway. This study was conducted to investigate the modulation of different players
implicated in the AKT survival pathway in PTH-induced intestinal cell apoptosis. We demonstrate, for the
ﬁrst time, that PTH modulates AKT phosphorylation in response to apoptosis via the serine/threonine
phosphatase PP2A. PTH treatment induces an association of AKT with the catalytic subunit of PP2A and
increases its phosphatase activity. PTH also promotes the translocation of PP2Ac from the cytosol to the
mitochondria. Furthermore, our results suggest that PP2A plays a role in hormone-dependent Caco-2 cells
viability and in the cleavage of caspase-3 and its substrate PARP. The cAMP pathway also contributes to PTH-
mediated AKT dephosphorylation while PKC and p38 MAPK do not participate in this event. Finally, we show
that PTH induces the dissociation between 14-3-3 and AKT, but the signiﬁcance of this response remains
unknown. In correlation with PTH-induced Bad dephosphorylation, the hormone also decreases the basal
association of 14-3-3 and Bad. Overall, our data suggest that in Caco-2 cells, PP2A and the cAMP pathway act
in concert to inactivate the AKT survival pathway in PTH-induced intestinal cell apoptosis.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is a form of programmed cell death that is character-
ized by speciﬁc morphological and biochemical features, and is
tightly regulated by extracellular stimuli and intracellular signaling
pathways [1]. There are two distinct signaling pathways of apoptosis
in mammals. One is initiated by death receptors (death receptor
pathways) [2], and the other is regulated by anti- and pro-apoptotic
Bcl-2 family members and involves release of cytochrome c from
mitochondria into the cytoplasm (mitochondrial pathways) [3,4]. It
has been suggested that the balance of pro- and anti-apoptotic
members of the Bcl-2 family determines life or death in a cell [5].
Indeed, the regulation of mitochondrial cytochrome c release and
mitochondrial function by several Bcl-2 family members plays a
large part in controlling cell death [3]. Bad, one of the pro-apoptotic
family members, is the ﬁrst target of AKT, a major inhibitor of
apoptosis [6]. By phosphorylating Bad, AKT precludes its binding to
the Bcl-xL and Bcl-2 anti-apoptotic family members leading to
increased cell survival. AKT, a serine/threonine protein kinase, is a
key component of cell survival pathways and is a major downstream
target of phosphoinositide 3-kinase (PI3K) [7]. Activation of PI3K
leads to AKT activation by both phosphoinositide-dependent protein
kinase-1 (PDK1), which phosphorylates AKT at Thr-308, and PDK1-
independent mechanisms, which result in AKT phosphorylation at
Ser-473 [7].0; fax: +54 291 4595130.
ll rights reserved.AKT phosphorylation is tightly regulated, representing a balance
between kinase-activating and phosphatase-inactivating events.
Several protein phosphatases, including the dual-action phosphatase
PTEN, which transforms PtdIns(3,4,5)P3 into PtdIns(4,5)P2 [8],
canonical PP1 [9,10] and PP2A [11–13] as well as newly identiﬁed
AKT phosphatases [14,15] were recently reported to bind and
dephosphorylate AKT in an agonist-dependent manner.
Mammalian PTH is an 84-amino acid single-chain polypeptide,
although only the ﬁrst 34 amino acids are required for most biological
effects [16,17]. The PTH receptor (PTH1R) is found in a variety of
tissues not regarded as classical PTH target tissues, including
intestinal cells [18,19]. In intestinal cells, PTH initiates its effects by
interacting with its PTHR1 that, like other members of the class II
family of GPCRs, is capable of coupling to several different G proteins,
thereby activating multiple signaling pathways, including adenylyl
cyclase/cAMP [20], PLC [21], cytoplasmic Ca2+ [22] and the MAP
kinases ERK1/2 [23] and p38 MAPK [24].
Apoptosis is especially relevant in the gastrointestinal tract, as the
mammalian intestinal mucosa undergoes a process of continual cell
turnover that is essential for maintenance of normal function [25].
Defective apoptosis may allow the progression of disease and
maintain the resistance of colon cancer cells to cytotoxic therapy
[26], again illustrating the importance of apoptosis in the gastroin-
testinal tract. Thus, it is of interest to know the mechanism as well as
the various physiological inducers of apoptosis in the intestinal
epithelium. Since PTH, depending on the cell type involved, inhibits or
promotes the apoptosis [27–29], we therefore used Caco-2 cells, a cell
line derived from human colorectal adenocarcinoma, as an in vitro
model for studying the effects of PTH on gut cell apoptosis. In a
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intestinal cells [30], which is mediated by translocation of mitochon-
dria to the perinuclear region, dephosphorylation of AKT, dephos-
phorylation of Bad and its movement to the mitochondria and
subsequent release of cytochrome c and Smac/Diablo which result in
activation of downstream caspase-3 and degradation of its substrate
PARP [30,31].
However, relatively little is known about how speciﬁc protein
tyrosine and serine/threonine phosphatases function to regulate PTH-
mediated apoptosis.
This study was conducted to investigate the modulation of
different players implicated in the AKT survival pathway in PTH-
induced intestinal cell apoptosis.
2. Materials and methods
2.1. Materials
Human PTH (1–34) was obtained from Calbiochem (San Diego, CA,
USA). High glucose Dubelcco's modiﬁed Eagle's medium (DMEM) was
from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum
(FBS) was from Natocord (Córdoba, Argentina).
Antibodies were from the following sources: anti-Bad, anti-
phospho-AKT (S473) anti-PP2Ac and anti-PARP were from Cell
Signaling Technology (Beverly, MA, USA). Anti-AKT1/2/3, anti-σ14-
3-3, anti-caspase-3, anti-cytochrome c, anti-lamin B and goat anti-
rabbit peroxidase-conjugated secondary antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Alexa Fluor 488 conjugat-
ed-anti-rabbit antibody was from Molecular Probes. Anti-actin
antibody, okadaic acid sodium and p-nitrophenyl phosphate (p-
NPP) were from Sigma (Sigma Chemical Co. St. Louis, MO, USA). Ro-
31-8220, Rp-cAMP (cyclic adenosine 3′,5′-mono-phosphorothioate,
Rp diastereomer) and SB 203580 were from Calbiochem (San Diego,
CA, USA).
Protein size markers were from Amersham Biosciences (Piscat-
away, NJ, USA), and PVDF (Immobilon polyvinylidene diﬂuoride)
membranes and ECL chemiluminescence detection kit were from
Amersham (Little Chalfont, Buckinghamshire, England). All other
reagents used were of analytical grade.
2.2. Cell culture and treatment
The human colon cell line Caco-2 (from the American Tissue
Culture Bank (Bethesda, USA)) was cultured at 37 °C in DMEM
containing 10% FBS, 1% non-essential acids, 100 UI/ml penicillin,
100 mg/ml streptomycin and 50 mg/ml gentamycin in a humid
atmosphere of 5% CO2 in air. Cultures were passaged every 2 days with
fresh medium. The treatments were performed with 70% conﬂuent
cultures in serum free medium by adding PTH (10−8 M) for 48 h.
Where indicated, cells were pretreated for 30 min with one of the
following inhibitors: okadaic acid sodium, LY 294002, Ro-31-8220,
Rp-cAMP or SB 203580. The inhibitors were also present during
subsequent exposure to the hormone.
2.3. Western blot analysis
Caco-2 cells were washed with PBS buffer plus 25 mM NaF and
1 mM Na3VO4, and lysed in buffer containing 50 mM Tris–HCl (pH
7.4), 150 mM NaCl, 3 mM KCl, 1 mM EDTA, 1% Tween-20, 1% Nonidet
P-40, 20 μg/ml aprotinin, 20 μg/ml leupeptin, 1 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF), 25 mM NaF and 1 mM Na3VO4. The lysates
were incubated on ice for 10min, vortexed for 45 s andmaintained on
ice for another 10 min. After centrifugation at 14,000×g and 4 °C
during 15 min the supernatant was collected and proteins were
quantiﬁed by the Bradford method [32]. Lysate proteins dissolved in
6× Laemmli sample buffer were separated (25 μg/lane) using SDS–polyacrylamide gels (10% or 15% acrylamide) and electrotransferred
to PVDF membranes. After blocking with 5% non-fat milk in TBST
buffer (50 mM Tris pH 7.2–7.4, 200 mM NaCl, 0.1% Tween-20), the
membranes were incubated overnight with the appropriate dilution
of primary antibody in TBST with 1% non-fat milk. After washing,
membranes were incubated with the appropriate dilution of horse-
radish peroxidase-conjugated secondary antibody in TBST with 1%
non-fat milk. Finally, the blots were developed by ECL with the use of
Kodak BioMax Light ﬁlm and digitalized with a GS-700 Imaging
Densitomer (Bio-Rad, Hercules, CA, USA).
2.4. Stripping and reprobing membranes
The complete removal of primary and secondary antibodies from
the membranes was achieved by incubating the membranes in
stripping buffer (62.5 mM Tris–HCl pH 6.8, 2% SDS and 50 mM β-
mercaptoethanol) at 55 °C for 30 min with agitation. Then,
membranes were washed for 10 min in TBST (1% Tween-20) and
blocked, as indicated above, for 1 h at room temperature. After that,
membranes were ready to reprobewith the corresponding antibodies.
2.5. Co-immunoprecipitation
Co-immunoprecipitation assays were performed under native
conditions in order to preserve protein–protein associations. To that
end, after hormone treatment, the cells were lysed in buffer A (50mM
Tris–HCl, pH 7.4, 150 mM NaCl, 3 mM KCl, 0.5 mM EDTA, 0.2 mM
Na3VO4, 1 mMNaF, 1 mM PMSF, 6 μg/ml leupeptin, 8 μg/ml aprotinin,
and 1% Tween-20). After centrifugation at 14,000×g (4 °C, 15 min)
the supernatant was collected and proteins were quantiﬁed by the
Bradford method [32]. Lysate aliquots (200–500 μg protein) were
incubated overnight at 4 °C with anti-Bad, anti-14-3-3, anti-AKT or
anti-PP2Ac antibodies, followed by precipitation of the complexes
with protein A conjugated with Sepharose. The immune complexes
were washed three times with buffer A (14,000×g, 4 °C, 5 min) and
then subjected to Western blot analysis. To conﬁrm the association of
both proteins, immunoprecipitation and immunoblotting were
performed with the same antibodies used in reverse order.
2.6. Protein phosphatase 2A (PP2A) activity assay
Cell lysates (200 μg protein) were incubated overnight at 4 °C with
anti-PP2Ac antibody, followed by precipitation of the complexes with
protein A conjugated with Sepharose. After three washes with lysis
buffer and two washes with a serine/threonine assay buffer (50 mM
Tris–HCl, pH 7.0, 100 μM CaCl2), the immune complexes were
incubated at 37 °C for 10 min in Ser/Thr assay buffer (45 μl/sample)
containing p-nitrophenyl phosphate as an exogenous substrate for
PP2A (5 μl/sample). The reaction was terminated by the addition of
NaOH 1N and the color developed was quantiﬁed by measuring the
absorbance with a spectrophotometer at 405 nm against a reagent
blank. The enzyme activity was expressed as percentage of the activity
respect of control.
2.7. Cell proliferation assay
The MTS assay (Promega) is based on the ability of viable cells to
bioreduce the tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt; MTS) into a colored formazan product that is soluble in tissue-
culture medium. The intensity of the product color is directly
proportional to the number of living cells in the culture. Cells were
seeded in 96-well plates at a density of 2×103 cells per well. After each
experiment, 20 μlMTSwas added toeachwell, followedby incubation for
45min at 37 °C. Absorbance was then measured with a spectrophotom-
eter at 490 nm. The results were expressed as a percentage of the mean
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without cells were used as negative controls.
2.8. Immunocytochemistry
Caco-2 cells grown onto glass cover slips were ﬁxed inmethanol at
−20 °C for 15 min. After washing with PBS, non-speciﬁc sites were
blocked with 5% BSA in PBS. Samples were then incubated overnight
with anti-PP2Ac antibody prepared in 2% BSA in PBS (1:50). After
washing with PBS, the samples were incubated for 1 h at room
temperature with secondary Alexa Fluor 488 conjugated antibody
(1:200). Cells were washed with PBS andmounted. Cells were stained
with MitoTracker Red CMXRos, (Molecular Probes) before ﬁxation to
visualize mitochondria [33]. It can be used to stain active mitochon-
dria and is retained after ﬁxation. The samples were examined using a
Leica TCS SP2 AOBS confocal laser microscope.
2.9. Subcellular fractionation
Cells were washed with PBS, resuspended in ice-cold TES buffer
(50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 250 mM sucrose containing
protease inhibitors) homogenized in a Teﬂon-glass hand homogeniz-
er (30 stokes), and then centrifuged at 1200×g for 20 min at 4 °C to
pellet the nuclei. The supernatant was centrifuged at 12,000×g for
20 min at 4 °C to pellet mitochondria. The resulting supernatant is the
cytosolic fraction. Nuclear and mitochondrial fractions were washed
twice in TES buffer. The purity of each isolated fraction was assessed
by assaying for proteins known to be associated with cellular
components. Routinely we included anti-lamin B and anti-cyto-
chrome c antibodies to check the purity of nuclear, mitochondrial and
cytosolic fractions. Proteins from each fraction were quantiﬁed by the
Bradford method [32]. Equal proteins from each fraction were
subjected to SDS–PAGE.
2.10. Statistical analysis
The statistical signiﬁcance of the data was evaluated using
Student's t test, and probability values below 0.050 (pb0.050) wereFig. 1. (A) Okadaic acid revert PTH-mediated AKT dephosphorylation. Caco-2 cells were pretrea
for 48 h. Proteins from cell lysates were immunoblottedwith anti-AKT phospho-Ser 473 antib
A representative immunoblot and bar graph from three independent experiments are sh
Interaction of PP2A with AKT in Caco-2 cells stimulated with PTH. Caco-2 cells were ex
immunoprecipitated (IP) with anti-AKT antibody under native conditions, resolved onto 10%
Materials and methods. Right side: The antibodies were used in reverse order. The m
Representative immunoblots from three independent experiments are given. (C) PTH increas
and assay of PP2A activity using p-nitrophenyl phosphate as substrate is detailed in Materials
respect to the control.considered signiﬁcant. Quantitative data are expressed as means±SD
from the indicated set of experiments.
3. Results
3.1. PTH increases PP2A activity, induces the association between PP2A
and AKT with subsequent dephosphorylation of AKT
Wehave recentlydemonstrated that the treatmentwithPTHcauseda
decrease in AKT basal phosphorylation at Ser-473 [31]. The contribution
of activation of protein phosphatases to PTH-induced dephosphorylation
of AKT was examined by pre-treating cells with the phosphatase
inhibitor okadaic acid (OA). OA inhibits the serine/threonine phospha-
tases to differing extents: has a 100-fold higher speciﬁcity for PP2A
(IC50_0.1 nM) than for PP1 (IC50_10nM) [34], PP2B is even less sensitive
(Ki 10 μM) and PP2C is not inhibited at all [35]. Initially, Caco-2 cells were
pre-incubated with different doses of OA (0.5–10 nM) followed by PTH
treatment (10−8 M, 48 h) and AKT phosphorylation was determined by
Western blot using a phospho-speciﬁc antibody against the Ser-473
residue. Maximal inhibition was observed at 1 nM okadaic acid, which
inhibited PP2A activity (not shown). OA at concentrations that inhibit
PP2A activity (1 nM) reverted PTH-mediated reduction of AKT
phosphorylation at Ser-473 (Fig. 1A). These results provided evidence
supporting a role for PP2A, rather than the related PP1, in regulating
cellular levels of phospho-AKT in intestinal cells exposed to PTH.
The previous observations demonstrated that PP2A activity
reduced phospho-AKT levels in cells exposed to PTH, but did not
demonstrate a direct interaction between the proteins. In order to
address whether PP2A exerted direct effects on AKT, we performed
co-immunoprecipitation assays under native conditions to preserve
protein–protein interactions. We found that PP2Ac could be detected
in AKT immunoprecipitates (Fig. 1B, left side), and in addition, AKT
was detected in equivalent PP2Ac immunoprecipitates (Fig. 1B, right
side). These results indicated that the catalytic subunit of PP2A
associates with AKT when Caco-2 cells are stimulated with PTH. To
study the effects of PTH on PP2A activity, the enzyme from lysates of
Caco-2 cells exposed to PTH for 48 h was immunoprecipitated with an
anti-PP2A catalytic subunit antibody and PP2A activity was thented for 30 min with okadaic acid (OA) (1 nM) followed by exposition to PTH (10−8 M)
ody and the same immunoblot was reprobedwith anti-AKT antibody as loading control.
own; means±SD are given. ⁎pb0.05 with respect to the corresponding control. (B)
posed to PTH (10−8 M) for 48 h. Left side: Cell lysates were obtained, AKT was
SDS–PAGE gels and then immunoblotted (IB) with anti-PP2Ac antibody as described in
embranes were dyed using Coomassie brilliant blue to demonstrate equal loading.
es PP2A activity in Caco-2 cells. Cells were incubated in presence of PTH (10–8M) for 48 h
and methods. Results are the average of three independent experiments. ⁎pb0.01 with
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As shown in Fig. 1C, PTH increased by 182% the activity of PP2A
compared with untreated cells.
3.2. PTH induces PP2A translocation to the mitochondria
Since the regulation of subcellular localization is important for the
ability of PP2A and other Ser/Thr phosphatases to dephosphorylate
particular substrates, we investigated the subcellular distribution of
the PP2A catalytic subunit in cells exposed to PTH (10−8 M, 48 h). As
shown in Fig. 2A, under basal conditions, PP2Ac localized to bothFig. 2. PTH promotes the translocation of PP2Ac from the cytosol to the mitochondria. (A) Cac
the mitochondrial and cytosolic fractions were isolated and the proteins were analyzed
Coomassie brilliant blue to demonstrate equal loading. A representative immunoblot and the
means±SD are given. ⁎pb0.05 with respect to the corresponding control. (B) Caco-2 cells w
methanol and incubated with a rabbit polyclonal antibody against PP2Ac. Fluorescence-conj
(green) and mitochondria (red) localization patterns under a confocal microscope. Red- ancytosolic and mitochondrial compartments. However, after PTH
treatment, the amount of the enzyme increased in the mitochondrial
fraction and decreased in cytosol, indicating that the hormone induces
the translocation of PP2Ac from the cytosol to themitochondria. These
results were conﬁrmed by confocal microscope (Fig. 2B).
3.3. PP2A mediates PTH decrease of live cells and the cleavage of
caspase-3 and its substrate PARP in Caco-2 cells
AKT is a key component of cell survival pathways and our results
show a role of PP2A in the dephosphorylation and inactivation of AKTo-2 cells were treated with or without PTH (10−8 M) during 48 h. Upon PTH treatment,
by Western blotting with an anti-PP2Ac antibody. The membranes were dyed using
quantiﬁcation by scanning densitometry of three independent experiments are shown;
ere treated with or without PTH (10−8 M) during 48 h. The cells were then ﬁxed with
ugated secondary antibody and MitoTracker Red CMX Ros were used to visualize PP2Ac
d green-stained images were merged. Areas of co-localization appear yellow.
Fig. 4. PP2A is involved in PTH-dependent caspase-3 activation and PARP degradation.
(A) Western blot analysis with an anti-caspase-3 antibody, speciﬁc for active caspase-3
(that recognizes p11 subunit), was performed to evaluate caspase-3 activation. (B)
Cleavage of poly (ADP-ribose) polymerase was analyzed by Western blotting with an
anti-PARP antibody that recognizes cleaved-PARP (89 kDa). In order to evaluate the
equivalence of protein content among the different experimental conditions, blotted
membranes were reprobed with anti-β-actin antibody. A representative immunoblot
and the quantiﬁcation by scanning densitometry of three independent experiments are
shown; means±SD are given. ⁎Pb0.05 with respect to the corresponding control.
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that PP2A affects cell viability, PTH treated cells (5 days) were
incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and,
upon treatment, the metabolic capacity of these intestinal cells was
measured as an indicator of cell viability. We found that PTH
diminished the bioreduction of the reagent, being the production
of formazan 56% lower respect to control (Fig. 3). Moreover, okadaic
acid (1 nM) reversed hormone-mediated decrease of live cells,
suggesting that PP2A activation mediates PTH-dependent apoptosis
in Caco-2 cells.
Our previous study showed that PTH activation of caspase-3 in
Caco-2 cells was followed by cleavage of its substrate poly (ADP-
ribose) polymerase PARP [31]. Therefore, we analyzed the cleavage
status of caspase-3 and PARP in cells exposed to PTH, and in the
presence or absence of OA (1 nM). Western blot analysis with an
anti-caspase-3 antibody speciﬁc for active caspase-3 (p11 subunit)
and with an anti-PARP antibody speciﬁc for PARP inactive fragment
of 89 kDa reveal the caspase-3 activation and the PARP
degradation in Caco-2 cells stimulated with PTH (48 h), effects
that were almost completely suppressed by OA, suggesting the
involvement of PP2A in the regulation of caspase-3 activity (Fig. 4A
and B). Actin immunoblotting was performed as an internal control
of equal protein loading.
3.4. Role of PKC, cAMP and p38 MAPK on PTH-dependent
AKT dephosphorylation
Since increased PP2A activity is an important component of PKC/
PKCα induced cell cycle arrest in intestinal epithelial cells [36], we
also investigated if PKC plays a role in PTH-mediated AKT dephos-
phorylation. To that end, the cells were treated with PTH (10−8 M,
48 h) in the presence of the PKC inhibitor Ro-31-8220 (200 nM)
followed by immunoblot analysis using a phospho-speciﬁc antibody
against the Ser-473 residue. We found that inhibition of PKC activity
did not reverse hormone-mediated reduction of AKT phosphorylation,
suggesting that PP2A activity on AKT is independent of PKC signaling
(not shown).
AKT is also phosphorylated at Ser-473 by the p38 MAPK-activated
protein kinase-2 (MAPKAPK-2) pathway [37,38]. Therefore, we also
have investigated the possible regulation of the PI3K/AKT survival
pathway by p38 MAPK in Caco-2 cells. To that end, cells were treated
with PTH (10−8 M, 48 h) in the presence of p38 MAPK speciﬁc
inhibitor, SB203580 (20 μM). Inhibition of the p38 MAPK did not
reverse hormone-mediated reduction of AKT phosphorylation, sug-
gesting that PP2A activity on AKT is independent of the p38 MAPK
pathway (not shown).Fig. 3. PP2A is involved in PTH-mediated decrease of live cells. Caco-2 cells were
pretreated for 30 min with okadaic acid (OA) (1 nM) followed by treatment with PTH
(10−8M) for 5 days. The ﬁrst control is in the absence of the agonist PTH and the second
control is in the presence of OA, without PTH. The number of viable cells was
determined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt) assay as described in Materials and
methods. Results are expressed as percentage relative to control of three independent
measurements performed in quadruplicate. ⁎pb0.05 with respect to the corresponding
control.cAMP can either stimulate [39–41] or inhibit [42–44] AKT activity.
Furthermore, there are reports describing cAMP-dependent PP2A
activation [45,46]. In an attempt to investigate whether the cAMP
pathway is involved in PTH-mediated AKT dephosphorylation, Caco-2
cells were treated with PTH (10−8 M, 48 h) in the presence of Rp-
cAMP (50 μM), a highly speciﬁc competitive antagonist for all
activators of the cAMP signal pathway, followed by immunoblot
analysis using a phospho-Ser-473-AKT antibody. As shown in Fig. 5A,
Rp-cAMP upregulated the levels of AKT phosphorylated on Ser473.
Moreover, PP2A activity signiﬁcantly decreased when Caco-2 cells
were incubated with Rp-cAMP followed by PTH treatment (Fig. 5B).
Taken together, these results indicate that the cAMP pathway
contributes to PP2A activation leading to the dephosphorylation and
inactivation of AKT.
3.5. PTH induces the dissociation of 14-3-3 with Bad and AKT in
Caco-2 cells
The 14-3-3 proteins are a family of adaptor and scaffolding
proteins that interact with more than 60 proteins and are involved
in cell cycle regulation, transcriptional control of gene expression, or
in apoptosis [47]. These proteins form homo- and heterodimers that
interact with phosphoserine binding domains [48]. There is
evidence that AKT interacts with and phosphorylates 14-3-3 Zeta,
leading to modulation of its dimerization [49]. To evaluate the
potential interaction between AKT and 14-3-3 in Caco-2 cells, we
Fig. 5. (A) Effect of Rp-cAMP on PTH-induced AKT dephosphorylation. Caco-2 cells were pretreated for 30 min with Rp-cAMP (50 μM) and were exposed to PTH (10−8 M) for 48 h
followed byWestern blot analysis of cell lysates with anti-AKT phospho-Ser 473 antibody. Blotted membranes were reprobed with anti-AKT antibody. A representative immunoblot
and the quantiﬁcation by scanning densitometry of three independent experiments are shown; means±SD are given. ⁎Pb0.05 with respect to the control. (B) cAMP is involved in
PTH-dependent PP2A activity. Caco-2 cells were pre-incubated for 30 min with Rp-cAMP (50 μM) and then exposed to PTH (10−8 M) for 48 h. PP2A activity assay using p-nitrophenyl
phosphate as substrate was performed as detailed in Materials and methods.
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to preserve protein–protein interactions. As shown in the Fig. 6A
(left side), the association of both proteins was detectable under
basal conditions and the treatment with PTH (10−8M, 48 h)
diminished the formation of the complex. This result was conﬁrmed
when the antibodies were used in reverse order (Fig. 6A, right side).
These data indicate that, in Caco-2 cells, the dephosphorylation and
inactivation of AKT by PTH lead to its dissociation from 14-3-3
protein, suggesting that the phosphorylation status of 14-3-3 and
perhaps its function might be affected. We have recently shown
that stimulation of Caco-2 cells with PTH results in the dephos-
phorylation of Bad, the ﬁrst target of AKT, and its movement from
the cytosol to mitochondria [31]. The phosphorylation of Bad results
in its binding to 14-3-3 protein in the cytosol and precludes its
binding to membrane-based Bcl-Xl, an event that enhances survival
[50]. However, with an apoptotic stimulus, Bad is dephosphorylated,
dissociates from 14-3-3 proteins, and translocates to the outer
membrane of mitochondria, where it subsequently dimerizes with
Bcl-Xl to neutralize their anti-apoptotic function [50]. To determine
whether Bad interacted with 14-3-3 in Caco-2 cells, we performed
co-immunoprecipitation experiments under native conditions fol-
lowed by Western blot analysis on immunoprecipitated 14-3-3 with
anti-Bad antibody. As shown in Fig. 6B (left side), PTH (10−8 M,
48 h) decreased the basal association of 14-3-3 and Bad, inFig. 6. (A) PTH induces the dissociation of 14-3-3 with AKT in Caco-2 cells. Caco-2 ce
immunoprecipitated (IP) with anti-14-3-3 antibody under native conditions, resolved onto 1
Materials and methods. Right side: The antibodies were used in reverse order. The m
Representative immunoblots from three independent experiments are given. (B) PTH induces th
for 48 h. Left side: In cell lysates 14-3-3was immunoprecipitated (IP)with anti-14-3-3 antibod
with anti-Bad antibody as described in Materials and methods. Right side: The antibodies w
demonstrate equal loading. Representative immunoblots from three independent experimentcorrelation with PTH-induced Bad dephosphorylation. Similar
results were obtained when the antibodies were used in reverse
order (Fig. 6B, right side). These results suggest that Bad
dephosphorylation [31] followed by its dissociation from 14-3-3
proteins is part of PTH-induced mitochondrial dysfunction leading
to Caco-2 cell apoptosis.
4. Discussion
PTH binding to its receptor is known to trigger initial tyrosine
phosphorylation events in intestinal cells, such as the activation of
MAP kinases and Src family kinases, that result in the activation of
downstream signaling pathways, a number of which involve the
activity of various serine/threonine kinases [21,23,51,52]. However,
relatively little is known about how speciﬁc protein tyrosine and
serine/threonine phosphatases function to regulate PTH-mediated
apoptosis. Like many physiological processes, commitment to apo-
ptosis is posttranslationally regulated by reversible phosphorylation
of apoptotic signaling proteins and therefore controlled by a balance
in protein kinase and protein phosphatase activity. We have recently
reported that PTH inhibits AKT phosphorylation in the human
intestinal cell line Caco-2 [31]. We now demonstrate that PTH
modulates AKT phosphorylation in response to apoptosis by activat-
ing the serine/threonine phosphatase PP2A.lls were exposed to PTH (10−8 M) for 48 h. Left side: In cell lysates 14-3-3 was
0% SDS–PAGE gels and then immunoblotted (IB) with anti-AKT antibody as described in
embranes were dyed using Coomassie brilliant blue to demonstrate equal loading.
e dissociation of 14-3-3with Bad in Caco-2 cells.Caco-2 cellswere exposed to PTH (10−8M)
y under native conditions, resolved onto 15% SDS–PAGE gels and then immunoblotted (IB)
ere used in reverse order. The membranes were dyed using Coomassie brilliant blue to
s are given.
Fig. 7. Pro-apoptotic events from PTH to PARP cleavage in Caco-2 cells. PTH induces the
activation of cAMP-PP2A pathway and the subsequent dephosphorylation and
inactivation of AKT leading to the activation of caspase-3 and degradation of its
substrate PARP.
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have been reported to contribute most of the Ser/Thr phosphatase
activity in cells [53]. PP2A is by far the best-characterized member
within the PP2/4/6 subclass, given that its catalytic, structural and
regulatory subunits have been sequenced and identiﬁed, and its
susceptibility to inhibition by compounds such as okadaic acid (OA)
and fostriecin is well known [54]. PP2A is an abundant and ubiquitous
enzyme with pleiotropic functions [55]. The predominant form of
PP2A in cells contains a heterotrimeric subunit structure, consisting of
a 36 kDa catalytic C subunit (PP2Ac), a 65 kDa structural A subunit
(PP2AA) and one of a variety of structurally distinct regulatory B
subunit (PP2AB). In addition to the heterotrimeric form of PP2A, core
dimeric form of PP2A consisting of A and C subunit also exists in cells.
The different B subunits are believed to change substrate speciﬁcity
and subcellular localization of PP2A [56]. This family of protein serine/
threonine phosphatases can interact with a substantial number of
proteins and contribute to the regulation of numerous signaling
pathways [54]. Active PP2A can inhibit the cell cycle, predominantly at
the G2/M checkpoint [57], induce apoptosis [58,59] and act as a tumor
suppressor [60]. The assumption that PP2A plays a key role in the
regulation of AKT, was supported by the ﬁnding that PTH increased
PP2A activity and induced its physical association with AKT.
Previous results in PC12 neuronal cells [61] hypothesize that
PP2A/Bβ2 holoenzyme exists in equilibrium between cytosol and
mitochondrial surface to promote dephosphorylation of unidentiﬁed
proteins associated with outer mitochondrial membrane, thus
inhibiting fusion and/or stimulating ﬁssion activities which in turn
sensitize neurons to pro-apoptotic insults [62]. Other pro-apoptotic
PP2A regulatory subunits appear to substitute for Bβ2 in non-
neuronal cells. Ruvolo et al. [63,64] reported that ceramide-induced
dephosphorylation of Bcl-2 in a lymphocyte cell line involves
mitochondrial redistribution of PP2A containing the B′ α regulatory
subunit. In line with these observations, our results show that, in
Caco-2 cells, PTH induced the translocation of PP2Ac from the cytosol
to the mitochondria.
Previous ﬁndings show that PP2A is a downstream target of p38
MAPK in TNF-induced endothelial apoptosis [65]. Furthermore, p38
MAPK has been shown to regulate PP2A in neutrophils and cardiac
myocytes [66,67]. However, PP2A has also been reported to
dephosphorylate the threonine residue of p38 MAPK and thereby
impair the activity of this protein [68]. In addition, PP2A activity is an
important component of PKC/PKCα induced cell cycle arrest in
intestinal epithelial cells [36]. Therefore, we further characterize the
mechanisms involved in PTH-mediated AKT dephosphorylation in
Caco-2 cells and our results rule out the participation of PKC and p38
MAPK in the hormone regulation of AKT but provide, for the ﬁrst time,
evidence that AKT is dephosphorylated by the phosphatase PP2A,
which in turn is activated by cAMP. In agreement with our ﬁndings,
the activation of cAMP-PP2A pathway and the subsequent inactiva-
tion of AKT also plays a key role in the induction of apoptosis in
Chinese hamster ovarian (CHO) cells [69]. The mechanistic details for
cAMP stimulation of PP2A are still unknown. In this regard, Hong et al.
[70] showed that cAMP-dependent inhibition of AKT in PCCL3 thyroid
cells is mediated by PP2A. They identiﬁed a novel and stable Epac–
PP2A signaling complex, and observed the modulation of its
phosphatase activity by Rap-GTP and PKA. Also, it has been recently
shown that cAMP could activate PP2A via PKA-dependent phosphor-
ylation of a B regulatory subunit [71,72].
There are studies showing that cAMP-inducing agents could be
used in the treatment of human colon cancer. The cAMP activator
forskolin with the cAMP phosphodiesterase-4 (PDE4) inhibitor
rolipram cause growth arrest and apoptosis of KM12C colon cancer
cells [73]. In DLD-1 cells, another colon cancer cell line, PDE4 plays a
critical role in regulating intracellular cAMP levels and is involved in
cancer invasion. Thus, PDE4 can be a novel target of anti-invasion drug
[74]. Furthermore, the human colon cancer cells LS174T are unable toproliferate upon sustained accumulation of intracellular cyclic AMP
following forskolin or dibutyryl cyclic AMP treatment [75].
Downstream target of AKT include caspase-9 [76] and phosphor-
ylation of this protein by AKT inhibits its pro-apoptotic function,
thereby favoring the survival-promoting effects of AKT [77]. In Caco-2
cells we hypothesize that after PTH treatment, dephosphorylation and
inactivation of AKT by PP2A revert caspase-9 inhibition, thereby
promoting its pro-apoptotic functions and thus activating caspase-3.
The AGC family of serine/threonine kinases includes AKT and PKC.
Interaction with various 14-3-3 isoforms has been reported to
stimulate [78] or to inhibit [79,80] PKC activity. Three phosphoryla-
tion sites have been identiﬁed on 14-3-3 proteins, Ser-58, Ser-184,
and Thr-232 [47] and some kinases have been found to phosphorylate
these residues, although the role of these phosphorylations in the
regulation of 14-3-3 function is unknown [81,82]. Ser-58 was
recognized as a low stringency AKT phosphorylation (2.703%) site
[83], suggesting that AKT might phosphorylate 14-3-3 proteins and
regulate a function common to both proteins. In Caco-2 cells, we
hypothesize that the dissociation between AKT and 14-3-3 induced by
PTH could affect the phosphorylation status of 14-3-3 and perhaps its
function, but additional studies are required to conﬁrm this idea.
Finally, we observed that, in correlation with PTH-induced Bad
dephosphorylation [31], PTH decreased the basal association of 14-3-3
and Bad. The deﬁned role for Bad is pro-apoptotic, in which it is
the nonphosphorylated species that binds Bcl-Xl to reverse death
protection [50]. The phosphorylation status of Bad appears to dictate
its subcellular localization as well as its capacity to associate with
14-3-3.
As summarized in Fig. 7, our results demonstrate that, in the
human intestinal cell line Caco-2, PTH increases the serine/threonine
phosphatase PP2A activity and that PP2A and the cAMP pathway act
in concert to inactivate the AKT survival pathway in hormone-induced
intestinal cell apoptosis.
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